Online inquiry

IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1835MR)

This product GTTS-WQ1835MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets IL17A gene. The antibody can be applied in Rheumatoid arthritis (RA) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens; Chimeric
RefSeq NM_002190.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3605
UniProt ID Q16552
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1835MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9456MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ8480MR IVTScrip™ mRNA-Anti-CD274, HTI-1088(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HTI-1088
GTTS-WQ16004MR IVTScrip™ mRNA-Anti-ERBB2, ZW-25(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ZW-25
GTTS-WQ3764MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ10055MR IVTScrip™ mRNA-Anti-FN1, L19-IL-2(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-IL-2
GTTS-WQ384MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 20D7S
GTTS-WQ3770MR IVTScrip™ mRNA-Anti-CEACAM6, BAY-1834942(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BAY-1834942
GTTS-WQ5082MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CAM-3001
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW